Defining the First Part of the Oncogenic KRAS Journey

Jihan K. Osborne; John D. Minna

doi:10.1016/j.stem.2020.09.009

Defining the First Part of the Oncogenic KRAS Journey

Jihan K. Osborne, John D. Minna

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Discovered as a proto-oncogene 40 years ago, mutations in KRAS exist in ∼30% of all human cancers. In this issue of Cell Stem Cell, Dost et al. (2020) combine the power of analyzing organoid cultures, patient samples, and mouse models with scRNA-seq to elucidate early events occurring with oncogenic KRAS activation.

Original language	English (US)
Pages (from-to)	499-500
Number of pages	2
Journal	Cell Stem Cell
Volume	27
Issue number	4
DOIs	https://doi.org/10.1016/j.stem.2020.09.009
State	Published - Oct 1 2020

ASJC Scopus subject areas

Molecular Medicine
Genetics
Cell Biology

Access to Document

10.1016/j.stem.2020.09.009

Cite this

@article{695eb4c6b2124e07a3b3ce109fa838b5,

title = "Defining the First Part of the Oncogenic KRAS Journey",

abstract = "Discovered as a proto-oncogene 40 years ago, mutations in KRAS exist in ∼30% of all human cancers. In this issue of Cell Stem Cell, Dost et al. (2020) combine the power of analyzing organoid cultures, patient samples, and mouse models with scRNA-seq to elucidate early events occurring with oncogenic KRAS activation.",

author = "Osborne, {Jihan K.} and Minna, {John D.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = oct,

day = "1",

doi = "10.1016/j.stem.2020.09.009",

language = "English (US)",

volume = "27",

pages = "499--500",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Defining the First Part of the Oncogenic KRAS Journey

AU - Osborne, Jihan K.

AU - Minna, John D.

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Discovered as a proto-oncogene 40 years ago, mutations in KRAS exist in ∼30% of all human cancers. In this issue of Cell Stem Cell, Dost et al. (2020) combine the power of analyzing organoid cultures, patient samples, and mouse models with scRNA-seq to elucidate early events occurring with oncogenic KRAS activation.

AB - Discovered as a proto-oncogene 40 years ago, mutations in KRAS exist in ∼30% of all human cancers. In this issue of Cell Stem Cell, Dost et al. (2020) combine the power of analyzing organoid cultures, patient samples, and mouse models with scRNA-seq to elucidate early events occurring with oncogenic KRAS activation.

UR - http://www.scopus.com/inward/record.url?scp=85091644824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091644824&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2020.09.009

DO - 10.1016/j.stem.2020.09.009

M3 - Article

C2 - 33007229

AN - SCOPUS:85091644824

SN - 1934-5909

VL - 27

SP - 499

EP - 500

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 4

ER -

Defining the First Part of the Oncogenic KRAS Journey

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this